Bob Lutz
Seminars
Tuesday 9th September 2025
Session Chair’s Opening Remarks
2:40 pm
- Novel Payloads as the New Value Driver for ADCs
- Why are new payloads needed?
- What new payloads are on the horizon?
- Case Study: Focusing on Iksuda’s novel protein alkylator (ProAlk) payload
Tuesday 9th September 2025
Novel & Dual Payloads: Assessing Linker Conjugation Technologies That Encourage Flexibility in Payloads
4:00 pm
- Evaluating the right ratios, the advantages of releasing drugs in specific ratios, and which combination of drugs make sense when considering dual payloads
- Discussing how novel payloads hold promise to overcome drug resistance
- Advancing cytoxic or immune-stimulating payloads with novel MoAs
Wednesday 10th September 2025
Increasing Tissue Penetration & Limiting Immunogenicity: Differentiating Through Novel Conjugate Design
1:40 pm
- Targeting proteins expressed in a larger number of cancers versus receptors predominantly expressed in solid tumor subsets
- Increasing tissue penetration propensity to achieve more significant internalization and intracellular exposure to the payload with smaller proteins
- Leveraging reduced screening cycles required to optimize linker chemistry with smaller proteins, and modulatory to conjugate different payload types
Wednesday 10th September 2025
Chair’s Closing Remarks
2:40 pm
Wednesday 10th September 2025
ADC Deal-Making: Will Success Lead to More Success?
2:10 pm
- Discussing opportunity for and examples of creative deal structures across ADCs
- For payloads: Do you need the full ADC payload for a deal?
- For linkers: What drives deals with different types of linkers?
- For target discovery: What are the differences in deal structure versus linkers and payloads?
- Sharing guidance to progress from a research collaboration to a licensing agreement, and deal structure including direction for upfront milestones and royalties
